MLYS — Mineralys Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1933414 ·
Last close
$14.48
Market Cap
$1.28B
52W High
$44.99
52W Low
$14.30
ADV30
1,808,812
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -60,087,000 | -57,328,000 | 630,123,000 | 101,273,000 | 126,348,000 |
| Jun 2026 | 0 | — | -246,040,000 | -241,071,000 | 667,853,000 | 138,268,000 | 116,936,000 |
| Mar 2026 | 0 | — | -45,340,000 | -39,339,000 | 652,862,000 | 112,779,000 | 14,718,000 |
| Dec 2025 | 0 | — | -38,280,000 | -32,234,000 | 661,806,000 | 172,921,000 | 15,113,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-153,011,000
Investing CF
$-328,951,000
Financing CF
$365,638,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.36
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-794,907,000
Inventory
—
Receivables
—
ST Investments
$523,399,000
EBIT TTM
$-383,800,000
Pretax Income TTM
$-369,972,000
Interest Exp TTM
$3,188,000
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -170,604,000 | -154,651,000 | 661,806,000 | 15,113,000 | 646,693,000 | -142,416,000 |
| Dec 2024 | 0 | -192,403,000 | -177,810,000 | 205,903,000 | 14,646,000 | 191,257,000 | -166,314,000 |
| Dec 2023 | 0 | -84,657,000 | -71,898,000 | 251,636,000 | 10,482,000 | 241,154,000 | -81,173,000 |
| Dec 2022 | 0 | -31,479,000 | -29,799,000 | 114,442,000 | 166,711,000 | -52,269,000 | -29,221,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-349,576,000
OpCashFlow TTM
—
Assets (Latest)
$667,853,000
Forward EPS
$-2.66
Max Pain — expiry 2027-01-15
max pain strike: $20.00 · spot: $13.78 · call oi: 30,971 · put oi: 1,687
Expected Move to 2027-01-15:
±$6.20
(44.99%) —
implied range
$7.58 –
$19.98
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GENB | Generate Biomedicines, Inc. | $1.27B | $9.84 | — |
| INVA | Innoviva, Inc. | $1.30B | $18.30 | — |
| GPCR | Structure Therapeutics Inc. | $1.30B | $18.17 | — |
| LBRX | LB PHARMACEUTICALS INC | $1.30B | $40.30 | — |
| MNKD | MANNKIND CORP | $1.31B | $4.07 | — |
News headlines (Yahoo Finance, 1h cache)
Mineralys stock gains after drug shows sustained blood pressure cuts
2026-11-09 17:59 · Yahoo
Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
2026-11-08 21:35 · Yahoo
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 13:00 · Yahoo
Mineralys Therapeutics Inc (MLYS) Q3 2026 Earnings Call Highlights: Strong Phase 3 Data and ...
2026-11-05 07:13 · Yahoo
Mineralys Therapeutics (MLYS) Publishes Lorundrostat CKD Data, Is The Stock Still A Bargain?
2026-11-05 05:18 · Yahoo
What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call
2026-11-05 03:14 · Yahoo
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-04 21:05 · Yahoo
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
2026-11-03 21:05 · Yahoo
Kidney Trial Results Could Change The Case For Mineralys Therapeutics Stock
2026-11-01 10:12 · Yahoo
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
2026-10-28 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.